Objective Evaluate whether adjuvanted quadrivalent influenza vaccine (aQIV) elicits a
noninferior immune response compared with a licensed adjuvanted trivalent influenza …

The current public health strategy for the containment of influenza is annual vaccination,
which is recommended for the elderly and for those in risk factor categories that present the …

Objective To compare the immunogenicity and safety between full-dose (15 μg)
intramuscular (IM) and full-dose (15 μg) intradermal (ID) immunization of the trivalent …

Background Influenza is associated with a high mortality and morbidity in older adults.
Vaccination remains the most effective method of preventing influenza and its …

An intradermal trivalent inactivated influenza vaccine administered using a microinjection
system has received European marketing authorization from the European Medicine …

Background The absolute degree of protection from influenza vaccines in older adults has
not been studied since 2001. This study aimed to show the clinical efficacy of an MF59 …

MF59®-adjuvanted trivalent inactivated influenza vaccine (aIIV3) and high-dose trivalent
inactivated influenza vaccine (HD-IIV3) elicit an enhanced immune response in older adults …

Introduction Immunosenescence makes the elderly more susceptible to influenza
complications and less responsive to vaccination. An intradermal formulation (IDflu) is one of …

Several approaches are currently being pursued in order to improve the efficacy of influenza
vaccines in elderly individuals and others who have impaired immune responses to …

Since the first reports of the A/H1N1 virus in April 2009, the pandemic influenza virus spread
globally and circulated for a long time. The primary method for the control of influenza is …